HOOK | tickerfilter.com

Fundamental analysis

33%

Profitability 21%

Dept financing 10%

Liquidity 75%

Performance 40%

Company vs Stock growth

4.703 M 1.354 M

-3.349 M -71.21%

3.140 1.500

-1.640 -52.23%

+ Add row to compare

Performance

5 Days

-4.07%

1 Month

-32.01%

3 Months

-56.13%

6 Months

-79.24%

1 Year

-4.01%

2 Year

11.92%

Key data

Stock price

$0.82

P/E Ratio

0.00

DAY RANGE

$0.76 - $0.89

EPS

-$4.47

52 WEEK RANGE

$0.48 - $6.77

52 WEEK CHANGE

-$3.03

MARKET CAP

24.230 M

YIELD

N/A

SHARES OUTSTANDING

9.655 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

1.30

PUBLIC FLOAT

AVERAGE 10 VOLUME

$69,129

AVERAGE 30 VOLUME

$51,304

Company detail

CEO: Jörn Aldag
Region: US
Website: www.hookipapharma.com
Employees: 160
IPO year: 2019

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

HOOKIPA Pharma Inc. develops immunotherapeutics targeting infectious diseases and cancers. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers.

HOOK - HOOKIPA Pharma Inc.